CD263 (TRAIL-R3) Antibody, anti-human, APC 130-104-788 from Miltenyi Biotec | Biocompare.com

Be the first to write a review!

Citations:

Supplier Page from
Miltenyi Biotec for
CD263 (TRAIL-R3) Antibody, anti-human, APC

The CD263 (TRAIL-R3) Antibody, anti-human, APC from Miltenyi Biotec is a Mouse Monoclonal antibody to TNFRSF10C. This antibody recognizes Homo Sapiens, and Human antigen. The CD263 (TRAIL-R3) Antibody, anti-human, APC has been shown to work in the following applications: Flow Cytometry.

Product Specs
ItemCD263 (TRAIL-R3) Antibody, anti-human, APC
CompanyMiltenyi Biotec
Price $145.00Supplier Page View Company Product Page
Catalog Number130-104-788
Regulatory StatusFor research use only
ApplicationsFlow Cytometry (FCM)
Concentration1:11
TypeAntibodies
Source/Expression Systemmouse
Research AreaFor research use only
ReactivityHuman (Hu)
Clonalitymonoclonal
NCBI Gene AliasesCD263, DCR1, DCR1-TNFR, LIT, TRAIL-R3, TRAILR3, TRID
NCBI Full Gene NameTNF receptor superfamily member 10c
Hostmouse
CloneDJR3
IsotypeIsotype Control Antibody, mouse IgG1
TargetCD263 (TRAIL-R3)
FormatReagents are supplied in buffer containing stabilizer and 0.05% sodium azide
Conjugate/TagAPC
Quantity30 tests in 300 µL

Add to Compare List

Miltenyi Biotec

Local Office

Miltenyi Biotec

Miltenyi Biotec Inc.

2303 Lindbergh Street

Auburn, CA 95602

United States

Phone: Phone: +1 530 888 8871
Toll Free: 800 FOR MACS
Fax: +1 530 888 8925

Email: macs@miltenyibiotec.com

Company Profile

Website: www.miltenyibiotec.com

International Office

Miltenyi Biotec

Miltenyi Biotec B.V. & Co. KG

Friedrich-Ebert-Straße 68

51429 Bergisch Gladbach

Germany

Phone: +49 2204 8306-0
Fax: +49 2204 8306-235

Email: macs@miltenyibiotec.de

Company Profile

Website: www.miltenyibiotec.com

(1) Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor developmentMolecular and cellular biologySeptember 1, 2007Ursini-Siegel J, Rajput AB, Lu H, Sanguin-Gendreau V, Zuo D, Papavasiliou V, Lavoie C, Turpin J, Cianflone K, Huntsman DG, et al.

(2) Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAILJournal of immunology (Baltimore, Md. : 1950)January 1, 1998Mongkolsapaya J, Cowper AE, Xu XN, Morris G, McMichael AJ, Bell JI, Screaton GR.

(3) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor familyThe Journal of experimental medicineOctober 6, 1997Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA.

Be the First to Write a Review!